Omazilumab: A Glimpse into Future Cancer Treatment

Omazilumab is an experimental monoclonal antibody being studied for its potential use in treating various forms of cancer.
Category
Drug
Where to get
Under research, not widely available
Applicable for
Monoclonal antibodies
Primary compound
Prepared by Lee Cheng, reviewed by Dr. Helena Rodriguez

Omazilumab FAQ


Image credit: si.edu

Does omalizumab increase cancer risk?

There is no evidence that omalizumab increases your risk of developing cancers. Studies using omalizumab have observed patients for up to one year after treatment and therefore long-term side effects are unknown. Can omalizumab increase the risk of having blood clots or a stroke?

Is omalizumab safe?

Omalizumab is a very safe medication, but you will be observed initially after your first few injections. No routine blood tests are required. Before or when you have your fourth dose in your first course of treatment, the dermatology team will ask if the therapy is working (please see the section ‘How is omalizumab given?’ above).

How is omalizumab dose chosen?

Your Omalizumab dose will be chosen based on your body weight and the results of a blood test that measures your level of IgE. You will receive 1-2 injections of Omalizumab in your upper arm depending on these factors. Unless your weight changes significantly, the dose and injection schedule should not change once your treatment has started.

Does Xolair contain omalizumab?

Xolair contains the active substance omalizumab. Omalizumab is a man-made protein that is similar to natural proteins produced by the body. It belongs to a class of medicines called monoclonal antibodies. Xolair is used for the treatment of: Allergic asthma

Omazilumab References

If you want to know more about Omazilumab, consider exploring links below:

Explore Related Topics

Immunotherapy for Asthma: Science vs. Experience

Contrast scientific evidence with personal experiences on the effectiveness of immunotherapy for asthma.